A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

被引:39
|
作者
Descamps, G. [1 ]
Gomez-Bougie, P. [1 ]
Venot, C. [2 ]
Moreau, P. [3 ]
Bataille, R. [1 ]
Amiot, M. [1 ]
机构
[1] Univ Nantes, UFR Med & Tech Med, Nantes Atlantique Univ,UMR 892, INSERM,Ctr Rech & Cancerol Nantes Angers, F-44000 Nantes, France
[2] Sanofi Aventis, Oncol Therapeut Dept, F-94403 Vitry Sur Seine, France
[3] Univ Nantes, CHU Nantes, UFR Med & Tech Med, Nantes, France
关键词
multiple myeloma; IGF-1/IGF-1R; bortezomib; CD45; translocation (4,14); MULTIPLE-MYELOMA; INHIBITION; THERAPY;
D O I
10.1038/sj.bjc.6604839
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45(neg) Myeloma patients, particularly those with the most aggressive form, t(4,14).
引用
收藏
页码:366 / 369
页数:4
相关论文
共 3 条
  • [1] A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
    G Descamps
    P Gomez-Bougie
    C Venot
    P Moreau
    R Bataille
    M Amiot
    British Journal of Cancer, 2009, 100 : 366 - 369
  • [2] Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
    Moreau, P.
    Cavallo, F.
    Leleu, X.
    Hulin, C.
    Amiot, M.
    Descamps, G.
    Facon, T.
    Boccadoro, M.
    Mignard, D.
    Harousseau, J. L.
    LEUKEMIA, 2011, 25 (05) : 872 - 874
  • [3] A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells
    Kawanami, Takako
    Takiguchi, Soichi
    Ikeda, Noriko
    Funakoshi, Akihiro
    ONCOLOGY REPORTS, 2012, 27 (03) : 867 - 872